NASDAQ · Biotechnology · USD
Turn Therapeutics Inc. (TTRX) Stock Analysis
Turn Therapeutics Inc. (TTRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TTRX Key Statistics
As of Oct 21, 2026Trading
- Open
- $10.61
- Previous Close
- $10.47
- Day's Range
- 10.15–10.62
- 52-Week Range
- 2.57–16.45
- Volume
- 60.57K
Valuation
- Market Cap
- $308.23M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.29
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$1.77M
- Shares Outstanding
- 30.37M
- 1-Year Return
- +114.14%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 102.91K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, TTRX closed at $10.15, +114.14% over 1 year.
Turn Therapeutics Inc. (TTRX) has a market capitalization of $308.23M.
In fiscal 2024, TTRX reported revenue of $0.00.
TTRX Stock Return by Calendar Year
Turn Therapeutics Inc. (TTRX) return since Oct 2025: what $10,000 became
- 1 year
- $10,000 $21,414
- +114.14%
- Since Oct 2025
- $10,000 $14,500
- +45.00%
If you had invested $10,000 in Turn Therapeutics Inc. (TTRX) at the close on October 8, 2025, the earliest close on record here, it would have been worth $14,500 at the close on October 21, 2026: +45.00% in total, +43.19% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +157.61% |
| 2025 (partial year) | −43.71% |
As of October 21, 2026.
TTRX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | −$1.77M | — |
| 2023 | $0.00 | −$2.29M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$1.80M | −$1.77M | — |
| 2023 | $0.00 | — | −$2.31M | −$2.29M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2024.
Recent News
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
BenzingaWBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
BenzingaTurn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
YahooTurn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
YahooTurn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B